InterPAD - DETAILS

41575-94-4, Carboplatin, Paraplatin, Cbdca, Carboplatinum, MFCD00070464, NSC-241240, cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II), cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), 1,1-Cyclobutanedicarboxylate diammine platinum(II), cis-Diammine(1,1-cyclobutanedicarboxylato)platinum, DTXSID3046742, CHEBI:31355, DTXCID201476080, NSC201345, NSC241240, Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-, Platinum(II),1-cyclobutanedicarboxylato)diammine-, cis-, Platinum,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-, Platinum,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)-, Epitope ID:194801, SCHEMBL4964, 1,1-Cyclobutanedicarboxylatodiammineplatinum(II), Paraplatin (Bristol Meyers), Lopac0_000230, HMS3269H03, Pharmakon1600-01502106, NSC758182, STL451040, Tox21_112586_1, NSC-758182, NCGC00167800-01, NCGC00263858-02, BP-25385, SY075575, CAS-41575-94-4, NS00076275, EN300-123065, AB01273939-01, azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+), 7,7-diamino-6,8-dioxa-7-platinaspiro[3.5]nonane-5,9-dione, diamino[cyclobutane-1,1-dicarboxylato(2-)-kappa~2~O~1~,O~1~]platinum, Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-.kappa.O,.kappa.O'']-, (SP-4-2)-

No.	Title	Href
1	Triptolide enhances carboplatin-induced apoptosis by inhibiting nucleotide excision repair (NER) activity in melanoma. Front Pharmacol. 2023 Jun 1;14:1157433. doi: 10.3389/fphar.2023.1157433.	`Click`
2	Sulforaphene-Carboplatin Combination Synergistically Enhances Apoptosis by Disruption of Mitochondrial Membrane Potential and Cell Cycle Arrest in Human Non-Small Cell Lung Carcinoma. J Med Food. 2016 Sep;19(9):860-9. doi: 10.1089/jmf.2016.3675.	`Click`
3	OSW-1 induces apoptosis and cyto-protective autophagy, and synergizes with chemotherapy on triple negative breast cancer metastasis. Cell Oncol (Dordr). 2022 Dec;45(6):1255-1275. doi: 10.1007/s13402-022-00716-2.	`Click`
4	Curcumin sensitizes carboplatin treatment in triple negative breast cancer through reactive oxygen species induced DNA repair pathway. Mol Biol Rep. 2022;49(4):3259-3270. doi:10.1007/s11033-022-07162-1.	`Click`
5	Astragaloside IV enhanced carboplatin sensitivity in prostate cancer by suppressing AKT/NF-κB signaling pathway. Biochem Cell Biol. 2021 Apr;99(2):214-222. doi: 10.1139/bcb-2020-0026.	`Click`
6	Chemopreventive effect of α-hederin/carboplatin combination against experimental colon hyperplasia and impact on JNK signaling. Toxicol Mech Methods. 2021 Feb;31(2):138-149. doi: 10.1080/15376516.2020.1849483.	`Click`

No.

Title

Href

Triptolide enhances carboplatin-induced apoptosis by inhibiting nucleotide excision repair (NER) activity in melanoma. Front Pharmacol. 2023 Jun 1;14:1157433. doi: 10.3389/fphar.2023.1157433.

Click

Sulforaphene-Carboplatin Combination Synergistically Enhances Apoptosis by Disruption of Mitochondrial Membrane Potential and Cell Cycle Arrest in Human Non-Small Cell Lung Carcinoma. J Med Food. 2016 Sep;19(9):860-9. doi: 10.1089/jmf.2016.3675.

Click

OSW-1 induces apoptosis and cyto-protective autophagy, and synergizes with chemotherapy on triple negative breast cancer metastasis. Cell Oncol (Dordr). 2022 Dec;45(6):1255-1275. doi: 10.1007/s13402-022-00716-2.

Click

Curcumin sensitizes carboplatin treatment in triple negative breast cancer through reactive oxygen species induced DNA repair pathway. Mol Biol Rep. 2022;49(4):3259-3270. doi:10.1007/s11033-022-07162-1.

Click

Astragaloside IV enhanced carboplatin sensitivity in prostate cancer by suppressing AKT/NF-κB signaling pathway. Biochem Cell Biol. 2021 Apr;99(2):214-222. doi: 10.1139/bcb-2020-0026.

Click

Chemopreventive effect of α-hederin/carboplatin combination against experimental colon hyperplasia and impact on JNK signaling. Toxicol Mech Methods. 2021 Feb;31(2):138-149. doi: 10.1080/15376516.2020.1849483.

Click

Name	Carboplatin
PubChem CID	426756
Molecular Weight	371.25g/mol
Synonyms	41575-94-4, Carboplatin, Paraplatin, Cbdca, Carboplatinum, MFCD00070464, NSC-241240, cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II), cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), 1,1-Cyclobutanedicarboxylate diammine platinum(II), cis-Diammine(1,1-cyclobutanedicarboxylato)platinum, DTXSID3046742, CHEBI:31355, DTXCID201476080, NSC201345, NSC241240, Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-, Platinum(II),1-cyclobutanedicarboxylato)diammine-, cis-, Platinum,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-, Platinum,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)-, Epitope ID:194801, SCHEMBL4964, 1,1-Cyclobutanedicarboxylatodiammineplatinum(II), Paraplatin (Bristol Meyers), Lopac0_000230, HMS3269H03, Pharmakon1600-01502106, NSC758182, STL451040, Tox21_112586_1, NSC-758182, NCGC00167800-01, NCGC00263858-02, BP-25385, SY075575, CAS-41575-94-4, NS00076275, EN300-123065, AB01273939-01, azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+), 7,7-diamino-6,8-dioxa-7-platinaspiro[3.5]nonane-5,9-dione, diamino[cyclobutane-1,1-dicarboxylato(2-)-kappa~2~O~1~,O~1~]platinum, Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-.kappa.O,.kappa.O'']-, (SP-4-2)-
Drug Type	Small molecule
Formula	C₆H₁₂N₂O₄Pt
SMILES	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
InChI	1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);21H2;/q;2-1;+2
InChIKey	VSRXQHXAPYXROS-UHFFFAOYSA-N
TTD ID	D0X7HM
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Triptolide, Carboplatin
Partner Name	Triptolide
Disease Info	[ICD-11: 2C30]	Melanoma		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Down-regulation	Activity	NR1H2	hsa7376
In Vitro Model	A-375	Amelanotic melanoma	Homo sapiens (Human)	CVCL_0132
In Vitro Model	B16	Mouse melanoma	Mus musculus (Mouse)	CVCL_F936
In Vivo Model	A375 cells were resuspended in 40% Matrigel (BD Biosciences) on ice, and then injected subcutaneously into the right axilla of the nude mice.
Result	This study reveals the NER inhibitor TPL which has great potential in treating melanoma, either alone or in combination with CBP.

Pair Name	Sulforaphene, Carboplatin
Partner Name	Sulforaphene
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	CASP3	hsa836
	Up-regulation	Expression	CASP9	hsa842
	Up-regulation	Expression	CYCS	hsa54205
	Down-regulation	Expression	JUN	hsa3725
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Phosphorylation	MAPK3	hsa5595
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	PIK3CA	hsa5290
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
Result	This study demonstrates that the duel character of this combination therapy may be an effective replacement for conventional therapy alone against NSCLC.

Pair Name	OSW-1, Carboplatin
Partner Name	OSW-1
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Autophagy
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAD	hsa572
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Up-regulation	Expression	BECN1	hsa8678
	Down-regulation	Expression	BIRC2	hsa329
	Down-regulation	Expression	BIRC3	hsa330
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Expression	CASP9	hsa842
	Up-regulation	Expression	MAP1LC3B	hsa81631
	Down-regulation	Expression	MCL1	hsa4170
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Down-regulation	Phosphorylation	PIK3CA	hsa5290
In Vitro Model	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
In Vivo Model	To generate 4T1 subcutaneous tumors, 1×10⁵ luciferase-expressing 4T1 cells were inoculated subcutaneously into the left-flanks of the mice.
Result	Our data revealed the mode of action and molecular mechanism underlying the effect of OSW-1 against TNBC, and provided a useful guidance for improving the sensitivity of TNBC cells to conventional chemotherapeutic drugs, which warrants further investigation.

Pair Name	Curcumin, Carboplatin
Partner Name	Curcumin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Up-regulation	Expression	H2AX	hsa3014
	Down-regulation	Expression	RAD51	hsa5888
	Up-regulation	Expression	ROS1	hsa6098
In Vitro Model	CAL-51	Breast carcinoma	Homo sapiens (Human)	CVCL_1110
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
Result	Our data demonstrate that curcumin sensitizes TNBC to the anticancer effect of carboplatin by increasing ROS-induced DNA damage, thus providing an effective combination treatment strategy for TNBC.

Pair Name	Astragaloside IV, Carboplatin
Partner Name	Astragaloside IV
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	NFKB1	hsa4790
	Up-regulation	Phosphorylation	NFKBIA	hsa4792
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Phosphorylation	RELA	hsa5970
In Vitro Model	LNCaP	Prostate carcinoma	Homo sapiens (Human)	CVCL_0395
In Vitro Model	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
In Vivo Model	AgIV synergized with carboplatin to suppress tumor xenograft growth of PC-3 cells, and decreased pAKT and p-p65 levels in vivo.
Result	Our results suggested that AgIV enhanced carboplatin sensitivity in prostate cancer cell lines by suppressing AKT/NF-κB signaling, thus suppressed epithelial-mesenchymal transition induced by carboplatin. Our findings provided a new mechanism for AgIV in overcoming drug resistance of platinum-based chemotherapy and suggested a potential combination therapy of AgIV and carboplatin in prostate cancer.

Pair Name	Alpha-Hederin, Carboplatin
Partner Name	Alpha-Hederin
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	CASP3	hsa836
	Down-regulation	Expression	CCND1	hsa595
	Up-regulation	Phosphorylation	MAPK8	hsa5599
	Up-regulation	Phosphorylation	PIK3CA	hsa5290
In Vivo Model	The running experiment was designed to test the chemopreventive activity of α-hederin when used as an adjuvant to carboplatin in an experimental model of mouse colon hyperplasia induced by 1,2-dimethylhydrazine (DMH). Fifty male Swiss albino mice were classified into five groups: group (I): saline group, group (II): DMH-induced colon hyperplasia control group, group (III): DMH + carboplatin (5 mg/kg) group, group (IV): DMH + α-hederin (80 mg/kg) group, and group (V): DMH + carboplatin (5 mg/kg)+α-hederin (80 mg/kg) group.
Result	Chemopreventive effect of α-hederin/carboplatin combination against experimental colon hyperplasia and impact on JNK signaling